LONDON - Britain launched a research program on Monday that should eventually allow all cancer patients to have access to the kind of genetic analysis that led Hollywood star Angelina Jolie to decide to undergo a double mastectomy.
NEW YORK - Fitness experts are shining a new light on group classes from Zumba to yoga because they believe the right lighting can transform the four walls of a fitness studio from a dance party to a meditation space, and back again.
DUBLIN - Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty Pharma.
WASHINGTON - The U.S. Supreme Court on Monday agreed to hear a patent dispute concerning Medtronic Inc over medical devices it manufactures that give the heart electrical jolts when it fails to pump blood properly.
LONDON - AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just south of the English city the most likely site, property industry sources said.
NEW YORK (Reuters Health) - Boys who are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in elementary school are more likely to grow up to be obese adults than those who don't have the condition, a new study suggests.
- Peregrine Pharmaceuticals said it reached an agreement with the U.S. Food and Drug Administration on the design of a late-stage trial for its experimental lung cancer drug.
- Generic drugmaker Actavis Inc, itself the subject of takeover speculation, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
- Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels.
- XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.